RESUMO
Recent evidence suggests a much higher prevalence of human immunodeficiency virus type 1 (HIV-1) recombinants than previously anticipated. These recombinants arise from secondary HIV infections in individuals already infected with the virus. It remains unclear why some individuals acquire secondary HIV-1 infections and others do not. To address this question, a study was undertaken of a small cohort of chimpanzees with well-defined HIV-1 infection. After exposure to an infectious dose of heterologous primary isolate, 4 of 8 HIV-1 seropositive chimpanzees resisted secondary infection, whereas 2 naive controls became readily infected. Only animals who were immunologically boosted were protected. Protection from heterologous secondary exposure appeared to be related to the repertoire of the cytolytic CD8(+) T cell responses to HIV-1. Data suggested that immunologic boosting by HIV-1 antigens or exposure to subinfectious doses of virus may be important events in sustaining sufficient immunity to prevent secondary infections from occurring.
Assuntos
Vacinas contra a AIDS/administração & dosagem , Síndrome da Imunodeficiência Adquirida/imunologia , Síndrome da Imunodeficiência Adquirida/prevenção & controle , Linfócitos T Citotóxicos/imunologia , Vacinas contra a AIDS/imunologia , Animais , Infecções por HIV/imunologia , Pan troglodytesRESUMO
Cell mediated immune responses to HIV-1 and CTL responses in particular differ dramatically in infected individuals. This may largely be influenced by the immunogenetic differences of different individuals such as those encoded by the MHC. These differences may be difficult to dissect due to the immunosuppressive nature of HIV-1 infection itself. In order to reduce the variables associated with effects of the virus, one recombinant viral antigen was chosen from a particular HIV-1 variant (rgp120 of the clinical isolate HIV-1w6.1D). To minimise differences between outbred hosts, we chose two sibling chimpanzees from which the family pedigree and genetic segregation with respect to polymorphic MHC molecules was known. Immunisation induced strong antigen specific antibody and T-helper immune responses. The magnitude and persistence of the humoral and T-helper immune responses were comparable in both chimpanzees. However, CTL responses were only observed in one sibling. These responses were subsequently mapped to several distinct epitopes. The CTL response to the immunodominant epitope was found to be presented in the context of a MHC molecule which was shared by both siblings. The absence of a CTL response in the other sibling is not yet understood, but could not be attributed to MHC alleles that were not shared by these two chimpanzees. These findings suggest that other polymorphic immunoregulatory mechanisms such as those involved in antigen processing and presentation influence host CTL responses to HIV-1.
Assuntos
HIV-1/imunologia , Antígenos de Histocompatibilidade Classe I/imunologia , Linfócitos T Citotóxicos/imunologia , Animais , Mapeamento de Epitopos , Epitopos de Linfócito T/imunologia , Feminino , Haplótipos , Humanos , Masculino , Pan troglodytes , LinhagemRESUMO
Certain HIV-1 infected humans that do not progress to AIDS have been documented to share particular MHC class I alleles that appear to correlate with long-term survival. HIV-1-infected chimpanzees are relatively resistant to progression to AIDS. Out of a group of 10 chimpanzees with CTL activity and nonprogressive HIV-1 infection, 2 animals with prominent cytolytic CD3+CD8+ T cell responses to HIV-1 Ags were studied in detail. Characterization of these CTL revealed that they contained the granzymes A and B, T cell intracellular Ag-1, and perforin and induced calcium-dependent cytolysis that correlated with the presence of apoptotic nuclei in target cells. These CTL responses were directed against two gagpeptides, which were found to be identical to previously described epitopes recognized in the context of HLA-B27 and HLA-B57 molecules. The latter two restriction elements occur with increased frequency in human long-term survivor cohorts. Phylogenetic comparisons revealed that the chimpanzee restriction elements, Patr-B*02and -B*03, described here do not show any obvious similarity with the HLA-B*27 and -B*57 alleles, suggesting that CTL responses to HIV-1 in distinct primate species may be controlled by different types of HLA-B-like molecules. The CTL responses in these two chimpanzees are directed, however, against highly conserved epitopes mapping across the majority of HIV-1 clades.
Assuntos
Síndrome da Imunodeficiência Adquirida/imunologia , Sequência Conservada/imunologia , Epitopos de Linfócito T/metabolismo , Sobreviventes de Longo Prazo ao HIV , HIV-1/imunologia , Pan troglodytes/imunologia , Linfócitos T Citotóxicos/imunologia , Síndrome da Imunodeficiência Adquirida/genética , Síndrome da Imunodeficiência Adquirida/veterinária , Sequência de Aminoácidos , Animais , Citotoxicidade Imunológica/genética , Mapeamento de Epitopos , Epitopos de Linfócito T/genética , Epitopos de Linfócito T/isolamento & purificação , Produtos do Gene gag/imunologia , Antígenos de Histocompatibilidade Classe I/genética , Antígenos de Histocompatibilidade Classe I/imunologia , Humanos , Imunofenotipagem , Dados de Sequência Molecular , Doenças dos Primatas/genética , Doenças dos Primatas/imunologia , Linfócitos T Citotóxicos/química , Linfócitos T Citotóxicos/metabolismoRESUMO
One of the obstacles to AIDS vaccine development is the variability of HIV-1 within individuals and within infected populations, enabling viral escape from highly specific vaccine induced immune responses. An understanding of the different immune mechanisms capable of inhibiting HIV infection may be of benefit in the eventual design of vaccines effective against HIV-1 variants. To study this we first compared the immune responses induced in Rhesus monkeys by using two different immunization strategies based on the same vaccine strain of HIV-1. We then utilized a chimeric simian/HIV that expressed the envelope of a dual tropic HIV-1 escape variant isolated from a later time point from the same patient from which the vaccine strain was isolated. Upon challenge, one vaccine group was completely protected from infection, whereas all of the other vaccinees and controls became infected. Protected macaques developed highest titers of heterologous neutralizing antibodies, and consistently elevated HIV-1-specific T helper responses. Furthermore, only protected animals had markedly increased concentrations of RANTES, macrophage inflammatory proteins 1alpha and 1beta produced by circulating CD8(+) T cells. These results suggest that vaccine strategies that induce multiple effector mechanisms in concert with beta-chemokines may be desired in the generation of protective immune responses by HIV-1 vaccines.
Assuntos
Vacinas contra a AIDS/administração & dosagem , Quimiocinas CC/imunologia , HIV-1/imunologia , Animais , Citocinas/imunologia , HIV-1/fisiologia , Imunidade Celular , Macaca mulatta , Testes de Neutralização , Linfócitos T/imunologia , Linfócitos T/virologiaRESUMO
HIV Pr55gag has in the absence of other viral components the capacity to self assemble in budding noninfectious virus-like particles (VLP). The immunological spectrum of the HIV-1IIIB gag-derived VLP was expanded either by stable anchoring of chimeric modified gp 120 on the surface of the VLP (type 1) or by replacing sequences of the Pr55gag precursor by the V3 loop and a linear portion of the CD4 binding domain (type 2). This noninfectious antigen delivery system was evaluated for immunogenicity and efficacy in rhesus macaques without adjuvants. Intramuscular immunization with both types of VLP induced high titers of gag-specific antibodies ranging from 1/8000 to 1/510,000 for type 1 VLP and from 1/4000 to 1/16,000 for type 2 VLP. Only animals immunized with type 1 VLP developed substantial endpoint titers of env-specific antibodies (1/2000-1/32,000) with a neutralizing capacity at serum dilutions of 1/32-1/128. Gag- and env-specific cytotoxic T lymphocyte (CTL) activity was induced by both types of VLP at similar levels. Four weeks after the last immunization animals were challenged intravenously with 20 MID50 of the cell free homologous envelope simian/HIV-1IIIB chimeric challenge stock Despite HIV-1-specific neutralizing and CTL responses, all vaccinated animals became infected.
Assuntos
Vacinas contra a AIDS/imunologia , Anticorpos Antivirais/imunologia , Citotoxicidade Imunológica , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Vírus da Imunodeficiência Símia/imunologia , Linfócitos T/imunologia , Vacinas contra a AIDS/administração & dosagem , Animais , Reações Cruzadas , Macaca mulatta , Vírus Reordenados/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle , Vírion/imunologiaRESUMO
Rhesus monkeys were successfully vaccinated using a strategy of priming with a candidate envelope subunit vaccine and boosting with synthetic peptides. Priming was carried out with recombinant HIV-1 SF2 envelope glycoprotein incorporated into ISCOMs, following the attachment of a lipid tail. Peptides, covalently linked to ISCOMs, representing linear sequences with the V2 and V3 regions, were used to boost functional antibodies-to neutralizing epitopes in both of these regions. Injections with these peptide formulations substantially increased the titre of serum neutralizing antibodies from low or undetectable levels. In addition to completely neutralizing the homologous HIV-1 SF2 strain, these sera also neutralized the escape variant, HIV-1 SF13. However, no antibodies were boosted which could compete with human, neutralizing monoclonal antibodies recognising conformational epitopes. The peptides also boosted antibodies to a peptide whose sequence lies close to the V2 region neutralizing epitope but does not overlap with it. Importantly, the level of antibodies to an unrelated epitope associated with enhancement of HIV-1 SF13 continued to fall after the peptide boost. Successful protection against challenge with chimeric simian immunodeficiency virus expressing HIV-1 SF13 envelope glycoproteins (SHIV SF13) may be due to an increase in the ratio of neutralizing to enhancing antibodies by selectively boosting with peptides to critical neutralizing epitopes.
Assuntos
Vacinas contra a AIDS/imunologia , Epitopos , Anticorpos Anti-HIV/sangue , Proteína gp120 do Envelope de HIV/imunologia , Vacinas Sintéticas/imunologia , Sequência de Aminoácidos , Animais , Humanos , Imunização Secundária , Macaca mulatta , Dados de Sequência MolecularRESUMO
To investigate whether Major Histocompatibility Complex (MHC) polymorphisms influence either susceptibility to SIV infection or progress to actual disease, rhesus monkeys were subjected to various forms of SIV infection and screened for allelic MHC heterogeneity by means of serological and biochemical methods. Animals that are protected against cell associated virus challenges were those that are SIV vaccinated and which shared a particular MHC class I allele (Mamu-A26) with the donor of the infected cells. Comparisons on the rate of infection to AIDS in SIVmac infected macaques showed that most Mamu-A26 positive animals belong to the group of long time survivors. In our outbred colony, about 25% of the rhesus macaques are positive for the Mamu-A26 serotype. Gel electrophoretic analyses demonstrated that isoelectric point (pI) differences of MHC class I heavy chains correlate with allotyping. In addition, the Mamu-A26 specificity was found to display heterogeneity. These results suggest that particular Mamu-A26 (associated) gene products may have the capacity or quality to induce antigen specific cytotoxic T lymphocyte responses that play a key role in controlling SIV infection or vaccine protection.
Assuntos
Complexo Principal de Histocompatibilidade/genética , Polimorfismo Genético/genética , Síndrome de Imunodeficiência Adquirida dos Símios/genética , Vírus da Imunodeficiência Símia/genética , Animais , Macaca mulatta , Doenças dos Macacos/genética , SobreviventesRESUMO
HIV-1 infected chimpanzees are relatively resistant to the development of AIDS despite their close genetic relatedness to humans and their susceptibility to HIV-1 infection. We have systematically studied possible reasons for their relative ability to maintain T helper (Th) cell numbers and immune competence in the presence of chronic HIV-1 infection. Factors which may alone or together cause the loss in T-cell dependent immunity include: (i) the loss of Th cell function; (ii) the loss of Th cells; and (iii) the loss of capacity for Th cell renewal. Differences in the in vivo and in vitro responses of T lymphocytes from chimpanzees and humans were compared for evidence of HIV-1 related T-cell dysfunction. In contrast to HIV infected individuals, HIV-1 infected chimpanzees maintained strong Th cell proliferative and cytokine responses after receiving tetanus toxoid boosts. In addition there was no abnormal Th1 to Th2 shift as is suggested to occur in AIDS patients. There was no evidence of Th cell dysfunction such as increased level of programmed cell death (PCD) or immune activation in HIV-1 infected chimpanzees in contrast to HIV-1 infected asymptomatic humans. Anergy could be induced with HIV-1 gp120 in human but not chimpanzee Th lymphocytes. We then asked if there was a direct loss of chimpanzee CD4+ cells due to HIV-1 infection in vitro. Infection of chimpanzee CD4+ lymphocyte cultures with HIV-1 in the absence of CD8+ cells resulted in marked cytopathic effect with complete lysis and loss of cells within 3 weeks. We concluded that most chronic HIV-1 infected chimpanzees were able to maintain relatively stable CD4+ lymphocyte numbers despite CD4+ lymphocyte destruction due to direct effects of the virus. Furthermore, there was no evidence of indirect Th cell loss, since neither increased levels of anergy nor apoptosis were observed. Lymph node biopsies from HIV-1 infected chimpanzees revealed that MHC class II rich regions of lymph nodes remained intact, in contrast to the involution of these regions in infected humans. This suggested that chimpanzees may maintain the capacity for Th cell renewal by preserving this MHC class II lymphoid environment. The data presented in this paper suggests that chimpanzees may preserve this critical MHC class II-Th cell environment by dramatically suppressing extra-cellular virus load and that this may be in part mediated by soluble lentivirus suppressing factors.
Assuntos
Infecções por Lentivirus/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/etiologia , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Animais , Progressão da Doença , HIV-1/imunologia , Antígenos de Histocompatibilidade Classe II/imunologia , Imunidade Inata , Pan troglodytes , Linfócitos T Auxiliares-Indutores/imunologia , Carga ViralRESUMO
Data from long-term non-progressing human immunodeficiency virus (HIV)-infected individuals and populations at high risk suggest that an early cytolytic T cell response rather than the humoral immune response might be involved in controlling disease progression. These observations may be used as a guide to the type of response that a vaccine should induce. To clarify the role of different arms of the immune system in conferring protection, the candidate vaccine should allow a regulated, selective induction of different immune responses. Based on a better understanding of the molecular mechanisms regulating the morphogenesis of HIV, we developed an autologous, non-replicating and safe antigen delivery system. This system takes advantage of molecular characteristics of the HIV group-specific antigens (gag) to self-assemble to highly immunogenic virus-like particles (VLP). The immunogenicity of the gag-derived VLP was expanded either by replacing defined domains by selected HIV-1 cytotoxic T lymphocyte (CTL) epitopes (type 1 VLP) or by stable anchoring derivatives of the HIV-1 envelope protein on the surface of the VLP (type 2 VLP). In complete absence of adjuvants, type 1 and type 2 VLP stimulated CD8+ CTL in BALB/c mice, which specifically recognised HIV sequences. In contrast to type 1 VLP, generating an HIV-specific CTL response in the absence of env-specific antibodies, type 2 VLP induced both arms of the immune system including reasonable levels of neutralising antibodies. Initial studies performed in rhesus macaques confirmed these results. Thus, depending on the type and formulation of the VLP, the proposed antigen delivery system allows either the induction of a CTL response (1) in the absence and (2) the presence of an envelope-specific antibody response. A comparison of these approaches in appropriate animal models might contribute to further define the correlates of protection.
Assuntos
Epitopos/imunologia , Produtos do Gene gag/imunologia , Vetores Genéticos , HIV/imunologia , Precursores de Proteínas/imunologia , Animais , Formação de Anticorpos , Linfócitos T CD8-Positivos/imunologia , Qualidade de Produtos para o Consumidor , Epitopos/genética , Expressão Gênica , Produtos do Gene gag/genética , HIV/genética , Anticorpos Anti-HIV/imunologia , Proteína gp120 do Envelope de HIV/genética , Humanos , Imunogenética , Macaca mulatta , Camundongos , Camundongos Endogâmicos BALB C , Testes de Neutralização , Precursores de Proteínas/genética , Recombinação Genética , Linfócitos T Citotóxicos/imunologia , Vírion/imunologia , Vírion/fisiologiaAssuntos
Vacinas contra a AIDS , Síndrome da Imunodeficiência Adquirida/imunologia , HIV-1/imunologia , Vacinas Sintéticas , Vacinas contra a AIDS/imunologia , Vacinas contra a AIDS/uso terapêutico , Síndrome da Imunodeficiência Adquirida/epidemiologia , Síndrome da Imunodeficiência Adquirida/terapia , Animais , China , Humanos , Camundongos , Camundongos Endogâmicos BALB C , Vacinas Sintéticas/imunologia , Vacinas Sintéticas/uso terapêuticoRESUMO
The efficacy of vaccine protection afforded by live attenuated vaccines was tested by heterologous SIVtno8980 challenge following successful protection against homologous SIVmac32H challenge. Animals immunized with the attenuated SIVmacBK28 molecular clone were asymptomatic and virus isolation negative by quantitative virus isolation prior to challenge. Two groups of four animals previously immunized 5 years and 4 months (respectively) were challenged with 100 MID50 of SIVtno8980, as was a third group of four naive controls. All control animals that were challenged developed high levels of plasma antigenemia within 2 weeks of challenge and developed rapid Th/m cell loss whereas vaccinated animals did not. Quantitative virus isolation from peripheral blood mononuclear cells revealed that one of four animals in each group became virus isolation positive but that the virus load in the two vaccinated animals was markedly lower than in nonvaccinated controls. Studies are underway to determine the duration and immunological correlates of protection from AIDS.
Assuntos
Vacinas contra a SAIDS/imunologia , Vírus da Imunodeficiência Símia/imunologia , Animais , Imunização , Macaca mulatta , Testes de Neutralização , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Síndrome de Imunodeficiência Adquirida dos Símios/prevenção & controle , Síndrome de Imunodeficiência Adquirida dos Símios/virologia , Vírus da Imunodeficiência Símia/isolamento & purificação , Especificidade da Espécie , Fatores de Tempo , Vacinas Atenuadas/imunologia , Vacinas Sintéticas/imunologiaRESUMO
OBJECTIVE: To determine the value of (combinations of) synthetic peptides representing immunodominant sites on HIV-1/HIV-2 transmembrane proteins for the detection and discrimination between HIV-1 and HIV-2 infection in various populations. DESIGN AND METHODS: Two 24-mer synthetic peptides derived from immunodominant sites on the HIV-1 and HIV-2 transmembrane proteins were used separately, in combination (env 1/2), and in combination with recombinant p24 (p24/env) in enzyme-linked immunosorbent assays. RESULTS: Positive reactions with env-1 were found in 150 out of 150 (100%) samples from Dutch AIDS patients, 60 out of 60 (100%) samples from Dutch homosexual men obtained 1 year after HIV-1-antibody seroconversion, 29 out of 30 (96.7%) samples from these men obtained at the time of HIV-1-antibody seroconversion, 40 out of 41 (97.6%) samples from East Africans with AIDS-related symptoms, and three out of 29 (10.3%) samples from West Africans with HIV-2 infection (including a sample from an individual infected with both HIV-1 and HIV-2). Positive reactions with env-2 in these study populations were 11 out of 150 (7.3%), nine out of 60 (15%), none out of 30 (0%), 25 out of 41 (60.9%) and 29 out of 29 (100%), respectively. In the samples with dual reactivity, true versus cross-reactivity could generally be differentiated on the basis of large differences in optical density values in the respective assays. All samples reacted positively with p24/env; 308 out of 310 (99.3%) were positive in the env 1/2 assay. Four East African samples that had negative or only weakly positive reactions with env-1 showed a noticeably stronger reaction with variant peptides derived from Central African isolate sequences. In all samples from HIV-1-infected Dutch homosexual men, the strongest signal was detected using the env-1 peptide sequence, which is derived from European and American isolates. CONCLUSIONS: Small peptide antigens may permit the detection of strain-specific antibodies, allowing serological characterization of HIV isolates.
Assuntos
Proteína gp41 do Envelope de HIV/genética , HIV-1/imunologia , África , Sequência de Aminoácidos , Variação Antigênica , Infecções por HIV/microbiologia , HIV-1/genética , HIV-2/genética , HIV-2/imunologia , Humanos , Masculino , Dados de Sequência Molecular , Peptídeos/síntese química , Peptídeos/genética , Peptídeos/imunologiaRESUMO
The in vitro synthesis of HIV-1, p24-, reverse transcriptase (RT)- and gp120-specific immunoglobulin (Ig) G by unstimulated peripheral blood mononuclear cells (PBMC) from 38 asymptomatic and 10 symptomatic HIV-1-seropositive individuals was analysed. In the majority of these individuals, spontaneous production of HIV-1- and gp120-specific IgG from PBMC cultures was demonstrated. In addition, in the majority of the PBMC cultures from individuals with high serum antibody titers to p24, spontaneous production of p24-specific IgG was shown. In contrast, no p24-specific IgG production was detected in PBMC cultures from seropositive individuals with low or no serum antibody titers to p24. A similar relationship between low or absent RT-specific serum antibody titers and the absence of in vitro RT-specific IgG synthesis was not demonstrated. Furthermore, it was shown that the number of p24-specific B lymphocytes in circulation, as calculated by a spot enzyme-linked immunosorbent assay, were significantly lower in individuals with low serum antibody titers to p24. These results suggest that the decline in p24-specific serum antibodies observed during progression towards AIDS is not merely a reflection of the clearance via immune complexes, but may also be attributable, at least in part, to a reduction of p24-specific antibody-producing active B lymphocytes.
Assuntos
Linfócitos B/imunologia , Soropositividade para HIV/imunologia , HIV-1 , Células Produtoras de Anticorpos/imunologia , Anticorpos Anti-HIV/sangue , Proteína do Núcleo p24 do HIV/sangue , Proteína do Núcleo p24 do HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , Transcriptase Reversa do HIV , Soropositividade para HIV/sangue , Soropositividade para HIV/tratamento farmacológico , HIV-1/imunologia , Humanos , Imunoglobulina G/biossíntese , Técnicas In Vitro , Contagem de Leucócitos , Masculino , DNA Polimerase Dirigida por RNA/imunologia , Zidovudina/uso terapêuticoRESUMO
An inhibition enzyme immunoassay (IEIA), using a human monoclonal antibody (K14) reactive with gp41 of HIV-1, was evaluated for its applicability to the serology of HIV-1 infections. Using panels of serum samples from seronegative and confirmed HIV-1-seropositive individuals, it was shown that all the HIV-1-positive samples in a panel from The Netherlands and 97% of the HIV-1-positive samples from Tanzania were identified by this IEIA. Six per cent of the IEIA-positive samples from Tanzania could not be confirmed in other assays. Testing of serial dilutions of serum samples from African individuals with confirmed HIV-1, HIV-2 or HIV(ANI70) infections in the K14 IEIA, indicated that a HIV-1-specific assay based on this principle may be developed.
Assuntos
Anticorpos Monoclonais/imunologia , Proteína gp41 do Envelope de HIV/imunologia , Infecções por HIV/diagnóstico , HIV-1/imunologia , Técnicas Imunoenzimáticas , Estudos de Avaliação como Assunto , HumanosRESUMO
A human Epstein-Barr virus-transformed lymphoblastoid B-cell line was generated from peripheral blood mononuclear cells (PBMC) of an asymptomatic human immunodeficiency virus type I (HIV-1) seropositive donor, which produces a human monoclonal antibody K14 (IgG1), reactive with an epitope on the transmembrane part (gp41) of the envelope glycoprotein of HIV-1. This monoclonal antibody reacts with a lysate of HIV-1-infected H9 cells, gradient purified HIV-1, and a vaccinia recombinant HIV-1 gp160 protein, but not with HIV-2 antigens in an enzyme-linked immunosorbent assay (ELISA). When used as an immobilized ligand in an immune affinity column, K14 selectively purifies gp41 from a HIV-1-infected H9 cell lysate. Although no reactivity was observed in ELISA with a panel of partially overlapping synthetic nonapeptides spanning the whole length of HIV-1 gp41, it was shown to react with recombinant envelope proteins, provided that they did contain amino acids 643-692: deletion of this part resulted in the disappearance of the reactivity. Testing of an extensive panel of the sera from HIV-1 seropositive or seronegative donors from Europe and Africa, including a selected group of donors before and after HIV-1 seroconversion, in a competition ELISA with horseradish peroxidase-conjugated K14, showed that the epitope recognized on gp41 is immunodominant and conserved. K14 does not neutralize HIV-1 infectivity or virus-mediated cell fusion, and does not mediate antibody-dependent cellular cytotoxicity.
Assuntos
Anticorpos Monoclonais/biossíntese , Epitopos/análise , Anticorpos Anti-HIV/biossíntese , HIV-1/imunologia , Proteínas do Envelope Viral/imunologia , Anticorpos Monoclonais/imunologia , Linfócitos B/imunologia , Ligação Competitiva , Transformação Celular Viral , Ensaio de Imunoadsorção Enzimática , Anticorpos Anti-HIV/imunologia , Herpesvirus Humano 4 , HumanosRESUMO
In a previous study we have shown that peripheral blood mononuclear cells (PBMC) from asymptomatic HIV-seropositive male homosexuals, who had seroconverted more than 2 years before, were unable to mount a secondary immune response in vitro to certain viral and bacterial antigens. We have extended this study by investigating the secondary immune responses of five male homosexuals, who, by regular screening, were found to have seroconverted for HIV-1 during the preceding 3 months and were subsequently vaccinated with tetanus toxoid and poliovirus vaccine. Six weeks after the booster vaccination, PBMC of the five recently seroconverted individuals were assayed for in vitro mitogen or recall antigen-induced antibody synthesis and lymphocyte proliferation. The results of this study indicate that certain of the in vitro abnormalities of immune reactions, observed in both symptomatic and asymptomatic HIV-seropositive individuals, can already be found within 3 months after seroconversion.
Assuntos
Soropositividade para HIV/imunologia , HIV-1/imunologia , Imunoglobulina G/biossíntese , Ativação Linfocitária , Linfócitos T CD4-Positivos , Células Cultivadas , Toxoide Diftérico/imunologia , Ensaio de Imunoadsorção Enzimática , Produtos do Gene gag/sangue , Anticorpos Anti-HIV/biossíntese , Proteína do Núcleo p24 do HIV , Humanos , Imunização Secundária , Memória Imunológica , Contagem de Leucócitos , Leucócitos Mononucleares/imunologia , Masculino , Vacina Antipólio de Vírus Inativado/imunologia , Linfócitos T Reguladores , Toxoide Tetânico/imunologia , Fatores de Tempo , Proteínas do Core Viral/sangueRESUMO
Five asymptomatic human immunodeficiency virus (HIV)-seropositive male homosexuals were immunized with the recall antigens tetanus toxoid (TT) and the three types of poliovirus present in diphtheria, tetanus, and polio vaccine. Four weeks after immunization, the in vivo response to booster immunization, the in vitro pokeweed mitogen (PWM)-induced IgG secretion, and the in vitro T cell-dependent and T cell-independent antigen-induced antibody response were assayed. Increase in serum antibody titer to TT and poliovirus was low and normal, respectively. In all five subjects studied, a high rate of spontaneous IgG production, including antibodies directed toward HIV was observed. Addition of PWM to the cultures induced suppression of the spontaneous IgG secretion. Only one donor showed a slightly increased IgG production after stimulation with PWM. Peripheral blood mononuclear cells of four of the five HIV-seropositive individuals did not produce TT, or poliovirus-specific antibodies when stimulated with the respective T cell-dependent antigens. However, stimulation of these peripheral blood mononuclear cells with TT coupled to agarose beads, which was shown to be T cell-independent, resulted in the generation of IgG anti-TT antibody-forming cells.
Assuntos
Formação de Anticorpos , Linfócitos B/imunologia , Soropositividade para HIV/imunologia , Linfócitos T/imunologia , Adulto , Células Apresentadoras de Antígenos/imunologia , Antígenos , Linfócitos B/citologia , Diferenciação Celular , Humanos , Memória Imunológica , Ativação Linfocitária , Cooperação Linfocítica , Mitógenos/farmacologia , Toxoide Tetânico/imunologiaRESUMO
The regulatory function of antigen-specific T cells in human antibody responses to protein and carbohydrate determinants of many viral and bacterial antigens has extensively been studied in systems involving in vitro triggering of B cells by antigens or polyclonal activators. Although amply documented in experimental murine models, the existence of T helper cells with receptor specificity for idiotypic determinants of B cell immunoglobulins has not been demonstrated in a human system. We are interested in T helper cell recognition of idiotypic determinants of virus-specific antibody, secreted by human B cells in response to viral antigens, and in the role which such idiotype-specific T helper cells play, alone or in concert with virus-specific T helper cells, to regulate the antibody response. Understanding of the function of different T helper cell subsets in an anti-viral antibody response and especially of the mechanisms of idiotype recognition by T cells is important for the development, and future application in man of idiotype vaccines, the potential of which has been indicated for different pathogens in several animal species. It was realized that for the efficient characterization of each of the T helper cell subsets, the availability of cloned populations of T cells would be inevitable. Furthermore, we argued that if, as predicted by Jerne, idiotype recognizing T helper cells are involved in physiological idiotype regulation in the course of an immune response--e.g., following encounter with virus--cloned populations of T cells should best be obtained by immunization protocols closely mimicking the physiological situation. In a previous report we described the induction of a secondary antibody response in human peripheral blood mononuclear cells (PBMC) in vitro by rabies virus antigen. This response was shown to be T helper cell dependent, and rabies virus-specific T helper cell clones have recently been obtained in our laboratory. The present study describes the generation of cloned lines of anti-idiotypic T4+ cells from rabies virus immune PBMC restimulated with rabies virus antigen in vitro. The cloned T cell lines were found to respond to circulating autologous antibody exhibiting specificity to rabies virus, but not to rabies virus antigen. The clonal proliferation, induced by this "auto-anticlonotypic" antibody, was found to be preceded by modulation of the T3/Ti molecular complex and required presentation of the antibodies by antigen presenting cells in association with HLA-DQ molecules. This observation of MHC-restricted idiotype recognition by human T cells, may have important consequences for the understanding of the regulation of th
Assuntos
Anticorpos Anti-Idiotípicos , Idiótipos de Imunoglobulinas , Linfócitos T/imunologia , Anticorpos Antivirais , Células Apresentadoras de Antígenos/imunologia , Linfócitos T CD4-Positivos/imunologia , Células Clonais/imunologia , Antígenos HLA-DQ , Humanos , Técnicas In Vitro , Ativação Linfocitária , Vírus da Raiva/imunologia , Receptores de Antígenos de Linfócitos TRESUMO
A patient with chronic B-cell leukemia in whom the malignant lymphocytes showed intracellular inclusions of immunoglobulin (Ig) G kappa molecules is described. Electron microscopy revealed filamentous material in the nuclear envelopes and in the cisternae of the rough endoplasmic reticulum. These in vivo surface Ig-negative, nonexcreting cells could be stimulated in vitro to excrete immunoglobulin-free light chain molecules into the supernatant, which were not found in the cytoplasm after stimulation.
Assuntos
Imunoglobulina G/análise , Leucemia/imunologia , Linfócitos/imunologia , Idoso , Medula Óssea/imunologia , Doença Crônica , Eritrócitos/patologia , Eritrócitos/ultraestrutura , Feminino , Histocitoquímica , Humanos , Imunoeletroforese , Técnicas Imunoenzimáticas , Cadeias Leves de Imunoglobulina/análise , Leucemia/patologia , Ativação Linfocitária , Linfócitos/patologia , Linfócitos/ultraestrutura , Microscopia Eletrônica , Coloração e RotulagemRESUMO
A strategy for gene cloning in the cyanobacterium Anacystis nidulans R2 was developed which made use of a gene library constructed in a shuttle cosmid vector. The method involved phenotypic complementation of mutants with pooled cosmid DNA. The development of the procedure and its application to the cloning of a third gene involved in nitrate reduction are described.